Review
doi: 10.1111/his.12796.
Ductal carcinoma in situ - update on risk assessment and management
Affiliations
- PMID: 26768032
- DOI: 10.1111/his.12796
Item in Clipboard
Review
Ductal carcinoma in situ - update on risk assessment and management
Histopathology.
2016 Jan.
Abstract
Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.
Keywords: breast neoplasms; clinical markers; clinical pathology; patient care management.
© 2015 John Wiley & Sons Ltd.
Comment in
-
The Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast.Histopathology. 2016 Sep;69(3):522-3. doi: 10.1111/his.12977. Epub 2016 May 5. Histopathology. 2016. PMID: 27028714 No abstract available.
Similar articles
-
The molecular journey from ductal carcinoma in situ to invasive breast cancer.Cancer. 2008 May 15;112(10):2130-42. doi: 10.1002/cncr.23430. Cancer. 2008. PMID: 18383519 Review.
-
Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Breast. 2017. PMID: 27671693 Review.
-
Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.Cancer Treat Rev. 2017 Apr;55:163-172. doi: 10.1016/j.ctrv.2017.03.009. Epub 2017 Mar 31. Cancer Treat Rev. 2017. PMID: 28402908 Review.
-
Biology of ductal carcinoma in situ classification based on biologic potential.Am J Clin Oncol. 2006 Jun;29(3):305-10. doi: 10.1097/01.coc.0000198740.33617.2f. Am J Clin Oncol. 2006. PMID: 16755185 Review.
-
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928525 Free PMC article.
Cited by
-
Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804. Histopathology. 2023. PMID: 36482277 Free PMC article. Review.
-
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.BMC Cancer. 2018 Feb 3;18(1):129. doi: 10.1186/s12885-018-4013-6. BMC Cancer. 2018. PMID: 29394917 Free PMC article.
-
Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.Mod Pathol. 2020 Mar;33(3):354-366. doi: 10.1038/s41379-019-0367-9. Epub 2019 Sep 18. Mod Pathol. 2020. PMID: 31534203 Free PMC article.
-
National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons.Curr Oncol. 2021 Mar 29;28(2):1366-1375. doi: 10.3390/curroncol28020130. Curr Oncol. 2021. PMID: 33805352 Free PMC article.
-
Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.J Cancer Res Clin Oncol. 2023 Oct;149(13):11181-11191. doi: 10.1007/s00432-023-04895-9. Epub 2023 Jun 24. J Cancer Res Clin Oncol. 2023. PMID: 37354223 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
